Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis

Christopher J Cadham, Jinani C Jayasekera, Shailesh M Advani, Shelby J Fallon, Jennifer L Stephens, Dejana Braithwaite, Jihyoun Jeon, Pianpian Cao, David T Levy, Rafael Meza, Kathryn L Taylor, Jeanne S Mandelblatt, CISNET-SCALE Collaboration, Christopher J Cadham, Jinani C Jayasekera, Shailesh M Advani, Shelby J Fallon, Jennifer L Stephens, Dejana Braithwaite, Jihyoun Jeon, Pianpian Cao, David T Levy, Rafael Meza, Kathryn L Taylor, Jeanne S Mandelblatt, CISNET-SCALE Collaboration

Abstract

Objectives: Current guidelines recommend delivery of smoking cessation interventions with lung cancer screening (LCS). Unfortunately, there are limited data to guide clinicians and policy-makers in choosing cessation interventions in this setting. Several trials are underway to fill this evidence gap, but results are not expected for several years.

Methods and materials: We conducted a systematic review and meta-analysis of current literature on the efficacy of smoking cessation interventions among populations eligible for LCS. We searched PubMed, Medline, and PsycINFO for randomized controlled trials of smoking cessation interventions published from 2010-2017. Trials were eligible for inclusion if they sampled individuals likely to be eligible for LCS based on age and smoking history, had sample sizes >100, follow-up of 6- or 12-months, and were based in North America, Western Europe, Australia, or New Zealand.

Results: Three investigators independently screened 3,813 abstracts and identified 332 for full-text review. Of these, 85 trials were included and grouped into categories based on the primary intervention: electronic/web-based, in-person counseling, pharmacotherapy, and telephone counseling. At 6-month follow-up, electronic/web-based (odds ratio [OR] 1.14, 95% CI 1.03-1.25), in-person counseling (OR 1.46, 95% CI 1.25-1.70), and pharmacotherapy (OR 1.53, 95% CI 1.33-1.77) interventions significantly increased the odds of abstinence. Telephone counseling increased the odds but did not reach statistical significance (OR 1.21, 95% CI 0.98-1.50). At 12-months, in-person counseling (OR 1.28 95% CI 1.10-1.50) and pharmacotherapy (OR 1.46, 95% CI 1.17-1.84) remained efficacious, although the decrement in efficacy was of similar magnitude across all intervention categories.

Conclusions: Several categories of cessation interventions are promising for implementation in the LCS setting.

Keywords: Lung cancer screening; Meta-analysis; Smoking cessation.

Conflict of interest statement

Conflicts of Interest:

None declared.

Copyright © 2019 Elsevier B.V. All rights reserved.

Figures

Appendix B.2:. Odds of Smoking Cessation From…
Appendix B.2:. Odds of Smoking Cessation From Random-Effects Meta-Analysis of Trials with Smokers Potentially Eligible for Lung Screening Based on 7-day Point Prevalence of Abstinence at 12-Months by Primary Intervention Type (n= 40 Trials)*
Forest plots display weighted odds ratios and 95% confidence intervals of included trials. Trial weights are generated from a random effects analysis. Squares around point estimates indicate study weight relative to the lowest weighted study for each meta-analysis. The vertical dashed line represents the pooled odds ratio with the diamond representing the 95% confidence interval. * Some trials included more than one intervention of a differing generic type so that the sum of the sample of all intervention types is greater than the total number of trials included.
Appendix B.3:. Sensitivity Analyses Examining Change in…
Appendix B.3:. Sensitivity Analyses Examining Change in Odds of Smoking Cessation From Random-Effects Meta-Analysis of Trials with Smokers Potentially Eligible for Lung Screening Based on 7-day Point Prevalence of Abstinence at 6-Months by Primary Intervention Type (n= 74 Trials)*
Forest plots display weighted odds ratios and 95% confidence intervals of included trials. Trial weights are generated from a random effects analysis. Squares around point estimates indicate study weight relative to the lowest weighted study for each meta-analysis. The vertical dashed line represents the pooled odds ratio with the diamond representing the 95% confidence interval. * Some trials included more than one intervention of a differing generic type so that the sum of the sample of all intervention types is greater than the total number of trials included.
Appendix B.3:. Sensitivity Analyses Examining Change in…
Appendix B.3:. Sensitivity Analyses Examining Change in Odds of Smoking Cessation From Random-Effects Meta-Analysis of Trials with Smokers Potentially Eligible for Lung Screening Based on 7-day Point Prevalence of Abstinence at 6-Months by Primary Intervention Type (n= 74 Trials)*
Forest plots display weighted odds ratios and 95% confidence intervals of included trials. Trial weights are generated from a random effects analysis. Squares around point estimates indicate study weight relative to the lowest weighted study for each meta-analysis. The vertical dashed line represents the pooled odds ratio with the diamond representing the 95% confidence interval. * Some trials included more than one intervention of a differing generic type so that the sum of the sample of all intervention types is greater than the total number of trials included.
Appendix B.3:. Sensitivity Analyses Examining Change in…
Appendix B.3:. Sensitivity Analyses Examining Change in Odds of Smoking Cessation From Random-Effects Meta-Analysis of Trials with Smokers Potentially Eligible for Lung Screening Based on 7-day Point Prevalence of Abstinence at 6-Months by Primary Intervention Type (n= 74 Trials)*
Forest plots display weighted odds ratios and 95% confidence intervals of included trials. Trial weights are generated from a random effects analysis. Squares around point estimates indicate study weight relative to the lowest weighted study for each meta-analysis. The vertical dashed line represents the pooled odds ratio with the diamond representing the 95% confidence interval. * Some trials included more than one intervention of a differing generic type so that the sum of the sample of all intervention types is greater than the total number of trials included.
Appendix B.5:. Contour-Enhanced Funnel Plots to Assess…
Appendix B.5:. Contour-Enhanced Funnel Plots to Assess Publication Bias of Smoking Cessation Interventions from a Random Effects Meta-Analysis by Intervention Type
Funnel plots compare the effect estimate of a study to some measure of its precision. Larger more powerful studies are placed at the top and smaller less powerful studies are at the bottom. Contour-enhanced funnel plots add areas of statistical significance to aid in the identification of areas of significance or non-significance from which studies appear to be missing.
Figure 1:. Selection of Trials Published from…
Figure 1:. Selection of Trials Published from 2010 to 2018 to Estimate the Efficacy of Smoking Cessation in Lung Screening-eligible Populations
The PRISMA diagram depicts the flow of studies through the phases of the systematic review from study identification to data analysis. A priori reasons for exclusion are presented at each stage.
Figure 2:. Odds of Smoking Cessation From…
Figure 2:. Odds of Smoking Cessation From Random-Effects Meta-Analysis of Trials with Smokers Potentially Eligible for Lung Screening Based on 7-day Point Prevalence of Abstinence at 6-Months by Primary Intervention Type (n= 74 Trials)*
Forest plots display weighted odds ratios and 95% confidence intervals of included trials. Trial weights are generated from a random effects analysis. Squares around point estimates indicate study weight relative to the lowest weighted study for each meta-analysis. The vertical dashed line represents the pooled odds ratio with the diamond representing the 95% confidence interval. * Some trials included more than one intervention of a differing generic type so that the sum of the sample of all intervention types is greater than the total number of trials included.

References

    1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J Med. 2011;365(5):395–409.
    1. De Koning HJ, Van der Aalst CM, ten Haaf K, Oudkerk M. Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. . IASLC WCLC 2018. Toronto; 2018.
    1. U.S.Preventive Services Task Force. Final Recommendation Statement: Lung Cancer: Screening. October 2014. Accessed December 18, 2017.
    1. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Lung Cancer Screening. 2017. Accessed December 18, 2017.
    1. Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer. 2007;56(1):125–34.
    1. Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013;119(7):1381–5.
    1. Slatore CG, Baumann C, Pappas M, Humphrey LL. Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. preventive services task force. Ann Am Thorac Soc. 2014;11(4):619–27.
    1. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). 2015. Accessed on December 18, 2017.
    1. Joseph AM, Rothman AJ, Almirall D, Begnaud A, Chiles C, Cinciripini PM, et al. Lung Cancer Screening and Smoking Cessation Clinical Trials: SCALE Collaboration. Am J Respir Crit Care Med. 2017.
    1. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; Accessed December 18, 2017; 2008.
    1. Taylor KL, Hagerman CJ, Luta G, Bellini PG, Stanton C, Abrams DB, et al. Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial. Lung Cancer. 2017;108:242–6.
    1. Clark MM, Cox LS, Jett JR, Patten CA, Schroeder DR, Nirelli LM, et al. Effectiveness of smoking cessation self-help materials in a lung cancer screening population. Lung Cancer. 2004;44(1):13–21.
    1. Ferketich AK, Otterson GA, King M, Hall N, Browning KK, Wewers ME. A pilot test of a combined tobacco dependence treatment and lung cancer screening program. Lung Cancer. 2012;76(2):211–5.
    1. van der Aalst CM, de Koning HJ, van den Bergh KA, Willemsen MC, van Klaveren RJ. The effectiveness of a computer-tailored smoking cessation intervention for participants in lung cancer screening: a randomised controlled trial. Lung Cancer. 2012;76(2):204–10.
    1. Marshall HM, Courtney DA, Passmore LH, McCaul EM, Yang IA, Bowman RV, et al. Brief Tailored Smoking Cessation Counseling in a Lung Cancer Screening Population is Feasible: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2016;18(7):1665–9.
    1. Iaccarino JM, Duran C, Slatore CG, Wiener RS, Kathuria H. Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review. Prev Med. 2019;121:24–32.
    1. Pineiro B, Simmons VN, Palmer AM, Correa JB, Brandon TH. Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: A systematic review. Lung Cancer. 2016;98:91–8.
    1. Bade M, Bahr V, Brandt U, Eigentopf A, Bruchert T, Gross ML, et al. Effect of smoking cessation counseling within a randomised study on early detection of lung cancer in Germany. J Cancer Res Clin Oncol. 2016;142(5):959–68.
    1. Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, et al. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(11):1430–68.
    1. National Institute for Health and Clinical Excellence, ed. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities NICE Public Health Guidance 10. London: National Institute for Health and Clinical Excellence, 2008.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, w64.
    1. VonVille HM: Excel workbooks for systematic reviews. .
    1. Rucker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8(4):392–403.
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
    1. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 ed: The Cochrane Collaboration; 2011.
    1. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149–59.
    1. Myung SK, McDonnell DD, Kazinets G, Seo HG, Moskowitz JM. Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(10):929–37.
    1. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–6.
    1. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28(2):105–14.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
    1. Catley D, Goggin K, Harris KJ, Richter KP, Williams K, Patten C, et al. A Randomized Trial of Motivational Interviewing: Cessation Induction Among Smokers With Low Desire to Quit. Am J Prev Med. 2016;50(5):573–83.
    1. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, Moreno SG. Assessing publication bias in meta-analyses in the presence of between-study heterogeneity. Journal of the Royal Statistical Society: Series A (Statistics in Society). 2010;173(3):575–91.
    1. Chen D, Wu LT. Smoking cessation interventions for adults aged 50 or older: A systematic review and meta-analysis. Drug Alcohol Depend. 2015;154:14–24.
    1. Zbikowski SM, Magnusson B, Pockey JR, Tindle HA, Weaver KE. A review of smoking cessation interventions for smokers aged 50 and older. Maturitas. 2012;71(2):131–41.
    1. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database of Systematic Reviews. 2017(3).
    1. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013(8):Cd002850.
    1. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013(5):Cd009329.
    1. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Cmaj. 2008;179(2):135–44.
    1. Charkhchi P, Kolenic GE, Carlos RC. Access to Lung Cancer Screening Services: Preliminary Analysis of Geographic Service Distribution Using the ACR Lung Cancer Screening Registry. J Am Coll Radiol. 2017;14(11):1388–95.
    1. Huo J, Hong YR, Bian J, Guo Y, Wilkie DJ, Mainous AG 3rd. Low Rates of Patient-Reported Physician-Patient Discussion about Lung Cancer Screening among Current Smokers: Data from Health Information National Trends Survey. Cancer Epidemiol Biomarkers Prev. 2019;28(5):963–73.
    1. Ladova K, Vlcek J, Vytrisalova M, Maly J. Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes. J Eval Clin Pract. 2014;20(2):111–6.
    1. Tammemagi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl. Cancer Inst. 2014;106(6):dju084.
    1. Abroms LC, Boal AL, Simmens SJ, Mendel JA, Windsor RA. A randomized trial of Text2Quit: a text messaging program for smoking cessation. American Journal of Preventive Medicine. 2014;47(3):242–50.
    1. Bock BC, Hudmon KS, Christian J, Graham AL, Bock FR. A tailored intervention to support pharmacy-based counseling for smoking cessation. Nicotine & Tobacco Research. 2010;12(3):217–25.
    1. Bolman C, Eggers SM, van Osch L, Te Poel F, Candel M, de Vries H. Is Action Planning Helpful for Smoking Cessation? Assessing the Effects of Action Planning in a Web-Based Computer-Tailored Intervention. Substance use & misuse. 2015;50(10):1249–60.
    1. Borland R, Balmford J, Benda P. Population-level effects of automated smoking cessation help programs: a randomized controlled trial. Addiction. 2013;108(3):618–28.
    1. Bricker JB, Mull KE, McClure JB, Watson NL, Heffner JL. Improving quit rates of web-delivered interventions for smoking cessation: full-scale randomized trial of versus . Addiction (Abingdon, England). 2017.
    1. Brown J, Michie S, Geraghty AWA, Yardley L, Gardner B, Shahab L, et al. Internet-based intervention for smoking cessation (StopAdvisor) in people with low and high socioeconomic status: a randomised controlled trial. The Lancet Respiratory Medicine. 2014;2(12):997–1006.
    1. Calhoun PS, Datta S, Olsen M, Smith VA, Moore SD, Hair LP, et al. Comparative Effectiveness of an Internet-Based Smoking Cessation Intervention Versus Clinic-Based Specialty Care for Veterans. Journal of substance abuse treatment. 2016;69:19–27.
    1. Choi SH, Waltje AH, Ronis DL, Noonan D, Hong O, Richardson CR, et al. Web-enhanced tobacco tactics with telephone support versus 1-800-QUIT-NOW telephone line intervention for operating engineers: randomized controlled trial. Journal of Medical Internet Research. 2014;16(11):e255.
    1. Cobos-Campos R, Apinaniz Fernandez de Larrinoa A, Saez de Lafuente Morinigo A, Parraza Diez N, Aizpuru Barandiaran F. Effectiveness of Text Messaging as an Adjuvant to Health Advice in Smoking Cessation Programs in Primary Care. A Randomized Clinical Trial. Nicotine & Tobacco Research. 2017;19(8):901–7.
    1. Free C, Knight R, Robertson S, Whittaker R, Edwards P, Zhou W, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet. 2011;378(9785):49–55.
    1. Gilbert HM, Leurent B, Sutton S, Alexis-Garsee C, Morris RW, Nazareth I. ESCAPE: a randomised controlled trial of computer-tailored smoking cessation advice in primary care. Addiction. 2013;108(4):811–9.
    1. Houston TK, Delaughter KL, Ray MN, Gilbert GH, Allison JJ, Kiefe CI, et al. Cluster-randomized trial of a web-assisted tobacco quality improvement intervention of subsequent patient tobacco product use: a National Dental PBRN study. BMC Oral Health. 2013;13:13.
    1. Houston TK, Sadasivam RS, Allison JJ, Ash AS, Ray MN, English TM, et al. Evaluating the QUIT-PRIMO clinical practice ePortal to increase smoker engagement with online cessation interventions: a national hybrid type 2 implementation study. Implementation Science. 2015;10:154.
    1. Leykin Y, Aguilera A, Torres LD, Perez-Stable EJ, Munoz RF. Interpreting the outcomes of automated internet-based randomized trials: example of an International Smoking Cessation Study. Journal of Medical Internet Research. 2012;14(1):e5.
    1. Loughead J, Falcone M, Wileyto EP, Albelda B, Audrain-McGovern J, Cao W, et al. Can brain games help smokers quit?: Results of a randomized clinical trial. Drug & Alcohol Dependence. 2016;168:112–8.
    1. Mason D, Gilbert H, Sutton S. Effectiveness of web-based tailored smoking cessation advice reports (iQuit): a randomized trial. Addiction. 2012;107(12):2183–90.
    1. Moskowitz JM, McDonnell DD, Kazinets G, Lee H. Online smoking cessation program for Korean Americans: Randomized trial to test effects of incentives for program completion and interim surveys. Preventative Medicine: An International Journal Devoted to Practice & Theory. 2016;86:70–6.
    1. Reitzel LR, McClure JB, Cofta-Woerpel L, Mazas CA, Cao Y, Cinciripini PM, et al. The efficacy of computer-delivered treatment for smoking cessation. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1555–7.
    1. Richter KP, Shireman TI, Ellerbeck EF, Cupertino AP, Catley D, Cox LS, et al. Comparative and Cost Effectiveness of Telemedicine Versus Telephone Counseling for Smoking Cessation. Journal of Medical Internet Research. 2015;17(5):e113.
    1. Sherratt FC, Marcus MW, Robinson J, Field JK. Utilizing Lung Cancer Risk Prediction Models to Promote Smoking Cessation: Two Randomized Controlled Trials. American Journal of Health promotion : AJHP. 2016.
    1. Smit ES, de Vries H, Hoving C. Effectiveness of a Web-based multiple tailored smoking cessation program: a randomized controlled trial among Dutch adult smokers. Journal of Medical Internet Research. 2012;14(3):e82.
    1. Stanczyk NE, de Vries H, Candel MJJM, Muris JWM, Bolman CAW. Effectiveness of video- versus text-based computer-tailored smoking cessation interventions among smokers after one year. Preventive medicine. 2016;82:42–50.
    1. Westmaas JL, Bontemps-Jones J, Hendricks PS, Kim J, Abroms LC. Randomised controlled trial of stand-alone tailored emails for smoking cessation. Tobacco control. 2018;27(2):136–46.
    1. Wetter DW, McClure JB, Cofta-Woerpel L, Costello TJ, Reitzel LR, Businelle MS, et al. A randomized clinical trial of a palmtop computer-delivered treatment for smoking relapse prevention among women. Psychology of Addictive Behaviors. 2011;25(2):365–71.
    1. Andrews JO, Mueller M, Dooley M, Newman SD, Magwood GS, Tingen MS. Effect of a smoking cessation intervention for women in subsidized neighborhoods: A randomized controlled trial. Preventive medicine. 2016;90:170–6.
    1. Bock BC, Papandonatos GD, de Dios MA, Abrams DB, Azam MM, Fagan M, et al. Tobacco cessation among low-income smokers: motivational enhancement and nicotine patch treatment. Nicotine & Tobacco Research. 2014;16(4):413–22.
    1. Brooks DR, Burtner JL, Borrelli B, Heeren TC, Evans T, Davine JA, et al. Twelve-Month Outcomes of a Group-Randomized Community Health Advocate-Led Smoking Cessation Intervention in Public Housing. Nicotine Tob Res. 2018;20(12):1434–41.
    1. Catley D, Goggin K, Harris KJ, Richter KP, Williams K, Patten C, et al. A Randomized Trial of Motivational Interviewing: Cessation Induction Among Smokers With Low Desire to Quit. American Journal of Preventive Medicine. 2016;50(5):573–83.
    1. Choi WS, Beebe LA, Nazir N, Kaur B, Hopkins M, Talawyma M, et al. All Nations Breath of Life: A Randomized Trial of Smoking Cessation for American Indians. American Journal of Preventive Medicine. 2016;51(5):743–51.
    1. Davis JM, Manley AR, Goldberg SB, Smith SS, Jorenby DE. Randomized trial comparing mindfulness training for smokers to a matched control. Journal of substance abuse treatment. 2014;47(3):213–21.
    1. Garvey AJ, Kalman D, Hoskinson RA Jr., Kinnunen T, Wadler BM, Thomson CC, et al. Front-loaded versus weekly counseling for treatment of tobacco addiction. Nicotine & Tobacco Research. 2012;14(5):578–85.
    1. Gifford EV, Kohlenberg BS, Hayes SC, Pierson HM, Piasecki MP, Antonuccio DO, et al. Does acceptance and relationship focused behavior therapy contribute to bupropion outcomes? A randomized controlled trial of functional analytic psychotherapy and acceptance and commitment therapy for smoking cessation. Behavior Therapy. 2011;42(4):700–15.
    1. Kim SS, Kim S-H, Fang H, Kwon S, Shelley D, Ziedonis D. A Culturally Adapted Smoking Cessation Intervention for Korean Americans: A Mediating Effect of Perceived Family Norm Toward Quitting. Journal of Immigrant & Minority Health. 2015;17(4):1120–9.
    1. Laude JR, Bailey SR, Crew E, Varady A, Lembke A, McFall D, et al. Extended treatment for cigarette smoking cessation: a randomized control trial. Addiction. 2017;112(8):1451–9.
    1. Okuyemi KS, Goldade K, Whembolua G-L, Thomas JL, Eischen S, Sewali B, et al. Motivational interviewing to enhance nicotine patch treatment for smoking cessation among homeless smokers: a randomized controlled trial. Addiction. 2013;108(6):1136–44.
    1. Pesis-Katz I, Williams GC, Niemiec CP, Fiscella K. Cost-effectiveness of intensive tobacco dependence intervention based on self-determination theory. American Journal of Managed Care. 2011;17(10):e393–8.
    1. Ramos M, Ripoll J, Estrades T, Socias I, Fe A, Duro R, et al. Effectiveness of intensive group and individual interventions for smoking cessation in primary health care settings: a randomized trial. BMC Public Health. 2010;10:89.
    1. Sheffer CE, Bickel WK, Franck CT, Panissidi L, Pittman JC, Stayna H, et al. Improving tobacco dependence treatment outcomes for smokers of lower socioeconomic status: A randomized clinical trial. Drug & Alcohol Dependence. 2017;181:177–85.
    1. Smith SS, Rouse LM, Caskey M, Fossum J, Strickland R, Culhane JK, et al. Culturally-Tailored Smoking Cessation for Adult American Indian Smokers: A Clinical Trial. The Counseling psychologist. 2014;42(6):852–86.
    1. Vidrine JI, Spears CA, Heppner WL, Reitzel LR, Marcus MT, Cinciripini PM, et al. Efficacy of mindfulness-based addiction treatment (MBAT) for smoking cessation and lapse recovery: A randomized clinical trial. J Consult Clin Psychol. 2016;84(9):824–38.
    1. Webb MS, de Ybarra DR, Baker EA, Reis IM, Carey MP. Cognitive-behavioral therapy to promote smoking cessation among African American smokers: a randomized clinical trial. Journal of Consulting & Clinical Psychology. 2010;78(1):24–33.
    1. Wewers ME, Shoben A, Conroy S, Curry E, Ferketich AK, Murray DM, et al. Effectiveness of Two Community Health Worker Models of Tobacco Dependence Treatment Among Community Residents of Ohio Appalachia. Nicotine & Tobacco Research. 2017;19(12):1499–507.
    1. Whiteley JA, Williams DM, Dunsiger S, Jennings EG, Ciccolo JT, Bock BC, et al. YMCA commit to quit: randomized trial outcomes. American Journal of Preventive Medicine. 2012;43(3):256–62.
    1. Williams GC, Niemiec CP, Patrick H, Ryan RM, Deci EL. Outcomes of the Smoker's Health Project: a pragmatic comparative effectiveness trial of tobacco-dependence interventions based on self-determination theory. Health Educ Res. 2016;31(6):749–59.
    1. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–20.
    1. Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. JAMA. 2016;315(4):371–9.
    1. Bullen C, Howe C, Lin R-B, Grigg M, Laugesen M, McRobbie H, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction. 2010;105(8):1474–83.
    1. Burns EK, Hood NE, Goforth E, Levinson AH. Randomised trial of two nicotine patch protocols distributed through a state quitline. Tobacco control. 2016;25(2):218–23.
    1. Caldwell BO, Crane J. Combination Nicotine Metered Dose Inhaler and Nicotine Patch for Smoking Cessation: A Randomized Controlled Trial. Nicotine & Tobacco Research. 2016;18(10):1944–51.
    1. Caldwell BO, Adamson SJ, Crane J. Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation. Nicotine & Tobacco Research. 2014;16(10):1356–64.
    1. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Archives of Internal Medicine. 2011;171(21):1901–7.
    1. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70(5):522–33.
    1. Cummings KM, Hyland A, Carlin-Menter S, Mahoney MC, Willett J, Juster HR. Costs of giving out free nicotine patches through a telephone quit line. Journal of Public Health Management & Practice. 2011;17(3):E16–23.
    1. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014;311(2):155–63.
    1. Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clinical Pharmacology & Therapeutics. 2014;96(3):390–6.
    1. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine & Tobacco Research. 2011;13(10):955–64.
    1. Lerman C, Schnoll RA, Hawk LW Jr., Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. The Lancet Respiratory Medicine. 2015;3(2):131–8.
    1. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Medicine. 2014;12:172.
    1. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine & Tobacco Research. 2012;14(3):343–50.
    1. Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. American Journal of Psychiatry. 2013;170(8):860–7.
    1. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Internal Medicine. 2015;175(4):504–11.
    1. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Annals of Internal Medicine. 2010;152(3):144–51.
    1. Selby P, Brosky G, Oh P, Raymond V, Arteaga C, Ranger S. A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION). BMC Public Health. 2014;14:433.
    1. Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction. 2013;108(12):2193–201.
    1. Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. European Respiratory Journal. 2012;40(3):548–54.
    1. Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. BMC Medicine. 2016;14:80.
    1. Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction. 2011;106(6):1176–85.
    1. Bastian LA, Fish LJ, Peterson BL, Biddle AK, Garst J, Lyna P, et al. Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks. American Journal of Health Promotion. 2013;27(3):181–90.
    1. Fu SS, van Ryn M, Nelson D, Burgess DJ, Thomas JL, Saul J, et al. Proactive tobacco treatment offering free nicotine replacement therapy and telephone counselling for socioeconomically disadvantaged smokers: a randomised clinical trial. Thorax. 2016;71(5):446–53.
    1. Klemperer EM, Hughes JR, Solomon LJ, Callas PW, Fingar JR. Motivational, reduction and usual care interventions for smokers who are not ready to quit: a randomized controlled trial. Addiction. 2017;112(1):146–55.
    1. Klesges RC, Ebbert JO, Talcott GW, Thomas F, Richey PA, Womack C, et al. Efficacy of a Tobacco Quitline in Active Duty Military and TRICARE Beneficiaries: A Randomized Trial. Military medicine. 2015;180(8):917–25.
    1. Lindqvist H, Forsberg LG, Forsberg L, Rosendahl I, Enebrink P, Helgason AR. Motivational interviewing in an ordinary clinical setting: a controlled clinical trial at the Swedish National Tobacco Quitline. Addictive Behaviors. 2013;38(7):2321–4.
    1. Maddison R, Roberts V, McRobbie H, Bullen C, Prapavessis H, Glover M, et al. Exercise counseling to enhance smoking cessation outcomes: the Fit2Quit randomized controlled trial. Annals of Behavioral Medicine. 2014;48(2):194–204.
    1. Nohlert E, Ohrvik J, Helgason AR. Effectiveness of proactive and reactive services at the Swedish National Tobacco Quitline in a randomized trial. Tobacco Induced Diseases. 2014;12(1):9.
    1. Sherman SE, Krebs P, York LS, Cummins SE, Kuschner W, Guvenc-Tuncturk S, et al. Telephone care co-ordination for tobacco cessation: randomised trials testing proactive versus reactive models. Tobacco control. 2018;27(1):78–82.
    1. Sumner W 2nd, Walker MS, Highstein GR, Fischer I, Yan Y, McQueen A, et al. A randomized controlled trial of directive and nondirective smoking cessation coaching through an employee quitline. BMC Public Health. 2016;16:550.
    1. Tzelepis F, Paul CL, Wiggers J, Walsh RA, Knight J, Duncan SL, et al. A randomised controlled trial of proactive telephone counselling on cold-called smokers' cessation rates. Tobacco control. 2011;20(1):40–6.
    1. Zhu S-H, Cummins SE, Wong S, Gamst AC, Tedeschi GJ, Reyes-Nocon J. The effects of a multilingual telephone quitline for Asian smokers: a randomized controlled trial. Journal of the National Cancer Institute. 2012;104(4):299–310.
    1. Zwar N, Richmond R, Halcomb E, Furler J, Smith J, Hermiz O, et al. Quit in general practice: a cluster randomised trial of enhanced in-practice support for smoking cessation. BMC Family Practice. 2010;11:59.
    1. Hall SM, Humfleet GL, Munoz RF, Reus VI, Prochaska JJ, Robbins JA. Using extended cognitive behavioral treatment and medication to treat dependent smokers. American Journal of Public Health. 2011;101(12):2349–56.
    1. Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Archives of Internal Medicine. 2010;170(6):543–50.
    1. Ramon JM, Nerin I, Comino A, Pinet C, Abella F, Carreras JM, et al. A multicentre randomized trial of combined individual and telephone counselling for smoking cessation. Preventive medicine. 2013;57(3):183–8.
    1. Smit ES, Candel MJJM, Hoving C, de Vries H. Results of the PAS Study: A Randomized Controlled Trial Evaluating the Effectiveness of a Web-Based Multiple Tailored Smoking Cessation Program Combined With Tailored Counseling by Practice Nurses. Health communication. 2016;31(9):1165–73.
    1. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine. 2010;38(5):482–90.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する